| Filed On | Filing |
|---|---|
| 16 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
THIS SECOND AMENDMENT TO AMENDED AND RESTATED LEASE (this "Second Amendment"), by and between SAN DIEGO INSPIRE 2, LLC, a Delaware limited liability company ("Landlord"), and ORGANOVO, INC., a Delaware corporation ("Tenant"), is made eff... |
| 06 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
to attract and retain the best available personnel for positions of substantial responsibility, |
| 21 Aug 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On August 17, 2026, VivoSim Labs, Inc., a Delaware corporation (the “Company”), received a written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
San Diego, CA — August 6, 2026 — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that on Augu... |
| 30 Jul 2026 |
8-K: Shareholder Director Nominations; Other Events
On July 30, 2026, the Board of Directors of VivoSim Labs, Inc. (the “Company”) set September 30, 2026 (the “Meeting Date”) as the date of the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”) and August 13, 2026 as the... |
| 24 Jul 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Other Events
On July 20, 2026, VivoSim Labs, Inc., a Delaware corporation (the “Company”), received a written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, since t... |
| 17 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This Securities Purchase Agreement (this “Agreement”) is dated as of July 16, 2026, between VivoSim Labs, Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on the signature pages hereto (including its su... |
| 03 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
SAN DIEGO, April 1, 2026 -- VivoSim Labs, Inc. (Nasdaq: VIVS), (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the pricing of up to a $4 million best-e... |
| 18 Dec 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On December 16, 2025, VivoSim Labs, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 2,607,962 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued ... |
| 14 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
On behalf of VivoSim Labs, Inc., and its subsidiaries, including, without limitation, namely Organovo Inc. and VivoSim, Inc. (“Company”), it is a great pleasure to extend you an offer of full-time employment as Chief Commercial Officer, ... |
| 06 May 2025 |
8-K: Other Events
As previously disclosed by VivoSim Labs, Inc. (the “Company”), on February 19, 2025, the Company received a written notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, sin... |
| 24 Apr 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure +1 more
The registered office of VivoSim Labs, Inc. shall be fixed in the corporation’s certificate of incorporation, as the same may be amended from time to time. |
| 23 Apr 2025 |
8-K: Regulation FD Disclosure
San Diego, CA – April 23, 2025 – Organovo Holdings, Inc. (Nasdaq: ONVO) (the “Company”) announced that it will carry forward its 3D bioprinting and legacy technology as VivoSim Labs, Inc. |
| 02 Apr 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
San Diego, CA – April 2, 2025 – Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today repo... |
| 27 Mar 2025 |
8-K: Regulation FD Disclosure
San Diego, CA – March 27, 2025 – Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today provi... |
| 26 Mar 2025 |
8-K: Completion of Acquisition or Disposition of Assets; Departure/Election of Directors or Officers; Compensation +1 more
San Diego, CA – March 25, 2025 – Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today anno... |
| 21 Mar 2025 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
CERTIFICATE OF THIRD AMENDMENTTO THECERTIFICATE OF INCORPORATIONOFORGANOVO HOLDINGS, INC. |
| 19 Mar 2025 |
8-K: Regulation FD Disclosure
SAN DIEGO, March 19, 2025 -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced that it will effect a 1-for... |
| 06 Mar 2025 |
8-K: Other Events
San Diego, CA – March 6, 2025 – Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announ... |
| 25 Feb 2025 |
8-K: Entry into a Material Definitive Agreement; Notice of Delisting or Failure to Satisfy a Listing Rule +1 more
***Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted information is indicated by brack... |
Loading...